Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.

Abstract

A posthoc analysis of the PIONEER1-5 and 8 trials assessed the clinically relevant composite endpoints of HbA1c (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide versus comparators. In the PIONEER trials, people with type2 diabetes were randomised to orally administered semaglutide versus placebo (PIONEER1, 4, 5 and 8), empagliflozin (PIONEER2), sitagliptin (PIONEER3) and liraglutide (PIONEER4) for 26-78weeks. This analysis assessed the proportion of people achieving an HbA1c reduction of ≥ 1% and body weight loss of ≥ 5% at week26 and at end of treatment, and the proportion of people achieving an HbA1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment. Overall, 3506 people in PIONEER1-5 and 8 were included. At week26 and at end of treatment, odds of achieving the composite endpoint of an HbA1c reduction of ≥ 1% and body weight loss of ≥ 5% were significantly greater with orally administered semaglutide 14mg than with placebo (PIONEER1, 4, 5 and 8; all p < 0.0001), empagliflozin 25mg (PIONEER2, p < 0.0001), sitagliptin 100mg (PIONEER3, p < 0.0001) and liraglutide 1.8mg (PIONEER4, p < 0.0001). Odds of achieving the composite endpoint of HbA1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment were also significantly greater with orally administered semaglutide versus comparators. In PIONEER1-5 and 8, odds of achieving clinically relevant reductions in both HbA1c and body weight were significantly greater with orally administered semaglutide versus comparators.